Laidlaw Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-104,841
| Closed | -$264K | – | 409 |
|
|
2021
Q3 | $264K | Sell |
104,841
-18,889
| -15% | -$47.6K | 0.07% | 198 |
|
|
2021
Q2 | $353K | Buy |
123,730
+8,000
| +7% | +$22.8K | 0.09% | 182 |
|
|
2021
Q1 | $272K | Sell |
115,730
-54,928
| -32% | -$129K | 0.09% | 174 |
|
|
2020
Q4 | $300K | Buy |
170,658
+37,990
| +29% | +$66.8K | 0.06% | 265 |
|
|
2020
Q3 | $124K | Buy |
132,668
+13,039
| +11% | +$12.2K | 0.06% | 200 |
|
|
2020
Q2 | $104K | Buy |
119,629
+12,250
| +11% | +$10.7K | 0.05% | 175 |
|
|
2020
Q1 | $89K | Buy |
107,379
+77,526
| +260% | +$64.3K | 0.06% | 145 |
|
|
2019
Q4 | $27K | Buy |
+29,853
| New | +$27K | 0.02% | 168 |
|